NCT01386619View on ClinicalTrials.gov

NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Leukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-LymphomaMyelodysplastic SyndromesLymphomaNeuroblastomaRhabdomyosarcoma
Interventions
BIOLOGICAL

CD3-depleted/CD56+ selected natural killer cells collected from apheresis products

NK DLI products containing \>1 10e7 NK cells/kg bodyweight (BW) and \< 1 x 10e5 T-cells/kg BW are administered at days +4 (Frankfurt only), and on days +40 and +100 (both centers)

Trial Locations (2)

Unknown

Universitätsklinikum, Frankfurt

University Hospital, Basel

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER

NCT01386619 - NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) | Biotech Hunter | Biotech Hunter